Calibrated Counterfactual Conformal Fairness ($C^3F$): Post-hoc, Shift-Aware Coverage Parity via Conformal Prediction and Counterfactual Regularization
校准反事实共形公平性:分布偏移下的覆盖率平等AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要以结构因果模型中的路径特定效应构建反事实正则项,提供因果方法方向的直接文本依据。
校准反事实共形公平性:分布偏移下的覆盖率平等AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
We present Calibrated Counterfactual Conformal Fairness ($C^3F$), a post-hoc procedure that targets group-conditional coverage parity under covariate shift. $C^3F$ combines importance-weighted conformal calibration with a counterfactual regularizer based on path-specific effects in a structural causal model. The method estimates group-specific nonconformity quantiles using likelihood-ratio weights so that coverage degrades gracefully with the second moment of the weights. We derive finite-sample lower bounds on group-wise coverage and a bound on the equalized conditional coverage gap, and we show first-order control of a counterfactual coverage-parity surrogate via smooth threshold regularization. The approach is model-agnostic, label-efficient, and deployable without retraining. Empirical evaluations on standard classification benchmarks demonstrate improved group-conditional coverage and competitive efficiency relative to shift-aware and fairness-oriented conformal baselines. We discuss practical considerations, including partial availability of sensitive attributes and robustness to structural causal misspecification.
连接局部与总体因果效应:近端工具变量方法
Instrumental variable (IV) methods address treatment endogeneity, but with non-compliance and heterogeneous treatment effects a binary instrument generally identifies the local average treatment effect (LATE) among compliers rather than the population average treatment effect (ATE). When treatment effects and compliance probabilities are heterogeneous and dependent through latent factors, the ATE need not be identified by IV variation alone. We develop a proximal…
基于方差的治疗效应异质性检验
This paper proposes a robust nonparametric hypothesis test for the existence of heterogeneous treatment effects. We focus on the variance of the Conditional Average Treatment Effect (CATE) as a natural omnibus parameter, where a non-zero variance implies the presence of relevant heterogeneity. Standard inference for this parameter faces a fundamental theoretical challenge. On one hand, evaluating variance components on the same sample leads to null degeneracy, where the…
以双重校准借用观察数据提升随机试验 CATE 估计精度
Understanding how treatment effects vary across patient characteristics is essential for personalized medicine, yet randomized controlled trials (RCTs) are often underpowered to detect heterogeneous treatment effects (HTEs). We propose a framework that improves the efficiency of conditional average treatment effect (CATE) estimation in RCTs by leveraging large observational studies (OS) while preserving RCT unbiasedness. Framing CATE estimation as a supervised learning…
主分层下异质性处理效应的双重交叉拟合去偏机器学习
Principal stratification provides a foundational framework for causal inference with intermediate outcomes by defining causal effects within subpopulations, yet existing work has largely focused on average effects across strata rather than treatment effect heterogeneity within strata. Such within-stratum heterogeneity informs individualized treatment decisions but the associated methods are sparse. We address this gap by studying the identification and estimation of the…
AMP 艾滋病预防试验中地区特异性生存效应的定向数据融合
The Antibody Mediated Prevention (AMP) trials opened a new scientific frontier by showing that passively administered monoclonal broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition. Conducted across multiple geographic regions, including the United States, Brazil, Peru, Switzerland, and sub-Saharan Africa, the AMP trials revealed substantial regional heterogeneity in treatment efficacy. These differences, together with privacy and regulatory limits on…
组间不平衡下的风险异质性稳健推断
Population-level heterogeneity is ubiquitous in biomedical data, where differences across demographic or clinical subgroups can substantially alter risk patterns. For example, in intensive care unit (ICU) studies, the mortality risk associated with specific admission diagnoses can vary across ethnic groups. Existing approaches for detecting risk heterogeneity are often sensitive to baseline model misspecification and regularization bias, both of which commonly arise in…